论文部分内容阅读
美国FDA于2012年7月17日批准美国VIVUS公司的芬特明-托吡酯(通用名:Phentermine-Top-iramate;商品名:Qsymia)缓释片上市,作为降低饮食热量及增加身体锻炼以外的辅助治疗,用于以下患者:初始体质量指数(BMI)大于或等于30kg/m2(肥胖)的患者;初始BMI大于或等于27kg/m2(超重)且伴有1种或多种与体质量相关并发
US FDA approved the release of Phentermine-Topiramate (generic name: Phentermine-Top-iramate; trade name: Qsymia) sustained release tablets from VIVUS Company of America on July 17, 2012 as a supplement to reduce calories and increase physical activity Treatment for patients with initial body mass index (BMI) greater than or equal to 30 kg / m2 (obesity); initial BMI greater than or equal to 27 kg / m2 (overweight) with one or more body mass related complications